Abstract
Hormonal contraceptives contain an Estrogen and/or a Progestin, which are the substrates of the CYP3A4 enzyme and the drugs inducing the CYP3A4 enzyme can decrease the plasma concentrations and thereby therapeutic efficacy of Hormonal contraceptives resulting in unintended pregnancy. Moreover, the hormonal contraceptives associated risk of thrombotic events are further exacerbated by the simultaneous administration of drugs like Tranexamic acid and tobacco smoke. Therefore, while prescribing hormonal contraception and other drugs to women, drug interactions should always be considered because there could be a possible contraceptive failure or other adverse drug effects. This article provides a summary of guidance to healthcare professionals such as prescribers and pharmacists on pharmacokinetic based interactions between hormonal contraception and other drugs.
| Original language | English |
|---|---|
| Pages (from-to) | 1219-1231 |
| Number of pages | 13 |
| Journal | Endocrine, Metabolic and Immune Disorders - Drug Targets |
| Volume | 21 |
| Issue number | 7 |
| DOIs | |
| State | Published - 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
-
SDG 5 Gender Equality
Keywords
- Drug interactions
- Ethinyl estradiol
- Hormonal contraceptives
- Pharma-codynamic interactions
- Pharmacokinetic interactions
- Progestin
Fingerprint
Dive into the research topics of 'Pharmacokinetic approach of clinically important drug interactions of hormonal contraceptives – a review'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver